- Home
- MOV vs ATXS Comparison
MOV vs ATXS Comparison
Compare MOV & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOV
- ATXS
- Stock Information
- Founded
- MOV 1961
- ATXS 2008
- Country
- MOV United States
- ATXS United States
- Employees
- MOV N/A
- ATXS N/A
- Industry
- MOV Consumer Specialties
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- MOV Consumer Discretionary
- ATXS Health Care
- Exchange
- MOV Nasdaq
- ATXS Nasdaq
- Market Cap
- MOV 339.1M
- ATXS 401.2M
- IPO Year
- MOV 1993
- ATXS 2015
- Fundamental
- Price
- MOV $16.21
- ATXS $6.03
- Analyst Decision
- MOV Strong Buy
- ATXS Strong Buy
- Analyst Count
- MOV 1
- ATXS 7
- Target Price
- MOV $31.50
- ATXS $32.43
- AVG Volume (30 Days)
- MOV 160.1K
- ATXS 310.9K
- Earning Date
- MOV 09-04-2025
- ATXS 08-11-2025
- Dividend Yield
- MOV 8.63%
- ATXS N/A
- EPS Growth
- MOV N/A
- ATXS N/A
- EPS
- MOV 0.78
- ATXS N/A
- Revenue
- MOV $650,768,000.00
- ATXS N/A
- Revenue This Year
- MOV $0.71
- ATXS N/A
- Revenue Next Year
- MOV N/A
- ATXS N/A
- P/E Ratio
- MOV $20.95
- ATXS N/A
- Revenue Growth
- MOV N/A
- ATXS N/A
- 52 Week Low
- MOV $12.85
- ATXS $3.56
- 52 Week High
- MOV $26.59
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- MOV 54.12
- ATXS 55.45
- Support Level
- MOV $15.96
- ATXS $6.20
- Resistance Level
- MOV $16.49
- ATXS $6.49
- Average True Range (ATR)
- MOV 0.44
- ATXS 0.37
- MACD
- MOV 0.02
- ATXS -0.02
- Stochastic Oscillator
- MOV 61.05
- ATXS 57.06
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.